CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,139 shares of the company’s stock after acquiring an additional 5,898 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in CRISPR Therapeutics were worth $1,422,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CRSP. Itau Unibanco Holding S.A. acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter worth $35,000. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC acquired a new position in CRISPR Therapeutics during the third quarter worth about $43,000. Elkhorn Partners Limited Partnership purchased a new position in CRISPR Therapeutics in the second quarter valued at about $54,000. Finally, Eastern Bank acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at approximately $70,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

CRSP has been the subject of several research analyst reports. Barclays dropped their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Bank of America dropped their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $39.04 on Thursday. The firm’s 50-day simple moving average is $45.46 and its 200-day simple moving average is $48.30. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $91.10. The firm has a market cap of $3.33 billion, a P/E ratio of -13.80 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the firm posted ($1.41) earnings per share. Analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.